Marker Therapeutics Gestione

Gestione criteri di controllo 2/4

Marker Therapeutics Il CEO è Juan Vera, nominato in May2023, e ha un mandato di 1.5 anni. la retribuzione annua totale è $ 585.25K, composta da 68.2% di stipendio e 31.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.99% delle azioni della società, per un valore di $ 828.27K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 6.3 anni.

Informazioni chiave

Juan Vera

Amministratore delegato

US$585.3k

Compenso totale

Percentuale dello stipendio del CEO	68.2%
Mandato del CEO	1.5yrs
Proprietà del CEO	3.0%
Durata media del management	1.5yrs
Durata media del Consiglio di amministrazione	6.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Oct 04

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Sep 13

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Aug 11

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Jun 17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Mar 04

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Nov 19

Marker Therapeutics: Passing Through A Catalyst Desert

Oct 22

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Aug 17

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

May 04

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Feb 22

Marker shares rise as it completes construction of its cGMP manufacturing facility

Jan 13

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Jan 05

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Dec 29

Marker Therapeutics EPS misses by $0.02

Nov 09

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Juan Vera rispetto agli utili di Marker Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$10m
Jun 30 2024	n/a	n/a	-US$10m
Mar 31 2024	n/a	n/a	-US$12m
Dec 31 2023	US$585k	US$399k	-US$14m
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$582k	US$380k	-US$20m

Compensazione vs Mercato: La retribuzione totale di Juan ($USD 585.25K ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 649.63K ).

Compensazione vs guadagni: La retribuzione di Juan è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Juan Vera (44 yo)

1.5yrs

Mandato

US$585,251

Compensazione

Dr. Juan F. Vera, MD, serves as Chief Executive Officer and President at Marker Therapeutics, Inc. since May 1, 2023 and serves as its Secretary and Treasurer. He has held various positions at the Center f...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Juan Vera	Co-Founder	1.5yrs	US$585.25k	2.99% $ 828.3k
Elizabeth Donnelly	Director of Administration	8.2yrs	Nessun dato	Nessun dato
Maria-Bernadette Madel	Director of Corporate Operations & External Communications	less than a year	Nessun dato	Nessun dato
Edmund Cheung	Vice President of Human Resources	1.8yrs	Nessun dato	Nessun dato
Monic Stuart	Chief Medical Officer	1.5yrs	Nessun dato	Nessun dato
Patricia Allison	Head of Clinical Operations	less than a year	Nessun dato	Nessun dato
Mary Newman	Head of Regulatory Affairs	less than a year	Nessun dato	Nessun dato
Robert Florkiewicz	Senior Director of Molecular Biology & Virology	no data	Nessun dato	Nessun dato

1.5yrs

Durata media

44yo

Età media

Gestione esperta: Il team dirigenziale di MRKR non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Juan Vera	Co-Founder	6.1yrs	US$585.25k	2.99% $ 828.3k
Steven Elms	Independent Director	5.3yrs	US$76.14k	0.033% $ 9.2k
James Allison	Member of Scientific Advisory Board	6.5yrs	Nessun dato	Nessun dato
Malcolm Brenner	Member of Scientific Advisory Board	6.8yrs	Nessun dato	Nessun dato
Cliona Rooney	Member of Scientific Advisory Board	6.8yrs	Nessun dato	Nessun dato
Norman Eansor	Independent Chairman	6.1yrs	US$124.04k	0.041% $ 11.5k
Padmanee Sharma	Member of Scientific Advisory Board	6.5yrs	Nessun dato	Nessun dato
John Wilson	Independent Director	6.1yrs	US$63.44k	8.76% $ 2.4m
Helen Heslop	Member of Scientific Advisory Board	6.8yrs	Nessun dato	Nessun dato
Katharine Knobil	Independent Director	2.9yrs	US$79.67k	0.0017% $ 464.7

6.3yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MRKR sono considerati esperti (durata media dell'incarico 6.3 anni).

Marker Therapeutics Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Marker Therapeutics, Inc. Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics, Inc. Announces Resignation of Anthony Kim as Chief Financial Officer, Effective September 30, 2022

Marker Therapeutics, Inc., Annual General Meeting, May 24, 2022

Marker Therapeutics, Inc. Announces Frederick Wasserman Will Not Stand for Reelection as Director

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.47 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.48 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: US$1.59 loss per share (vs US$3.58 loss in FY 2022)

Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

New major risk - Share price stability

Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study

Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse

Second quarter 2023 earnings released: US$0.47 loss per share (vs US$1.11 loss in 2Q 2022)

Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen (Multitaa)-Specific T Cell Product Candidate, Mt-401

Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration

Marker Therapeutics, Inc. Reports Pre-Clinical Data of Its MT-601 multiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics, Inc. Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLC

Marker Therapeutics Announces U.S. Food and Drug Administration Clearance of IND for MT-601, Its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

Consensus revenue estimates increase by 277%

Price target decreased to US$2.17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Resignation of Anthony Kim as Chief Financial Officer, Effective September 30, 2022

Marker Therapeutics Wins $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 Artemis Trial of Mt-401 in Post-Transplant AML

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Nasdaq Grants an Additional 180-Calendar Day Compliance Period to Marker Therapeutics to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 41%

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Marker Therapeutics, Inc. Announces FDA Clearance of IND for Mt-601, the Six-Antigen Targeted T Cell Therapy for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Price target decreased to US$3.63

Marker Therapeutics, Inc., Annual General Meeting, May 24, 2022

Marker Therapeutics, Inc. Announces Frederick Wasserman Will Not Stand for Reelection as Director

Full year 2021 earnings: EPS misses analyst expectations

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Clinical Program Updates and Pipeline Expansion

Price target decreased to US$5.63

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from Russell 3000E Value Index

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Earnings beat expectations, revenue disappoints

Marker Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Trial of Mt-401 in Acute Myeloid Leukemia Following Stem Cell Transplant

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

New 90-day high: US$3.19

Marker shares rise as it completes construction of its cGMP manufacturing facility

New 90-day high: US$1.79

Marker Therapeutics, Inc. Announces U.S. Food and Drug Administration Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

New 90-day high: US$1.75

Earnings beat expectations

Marker Therapeutics EPS misses by $0.02

New 90-day low: US$1.43

New 90-day low: US$1.50

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from S&P Global BMI Index

New 90-day low - US$1.65

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media